| Title | 滤泡性淋巴瘤新药研究进展 |
| Other Titles | Research progress on new agents for follicular lymphoma |
| Authors | 高珊 |
| Affiliation | 100191,北京大学第三医院血液科 |
| Keywords | 淋巴瘤,滤泡型 淋巴瘤,非霍奇金 药物疗法,联合 Lymphoma,follicular Lymphoma,non-Hodgkin Drug therapy,combination |
| Issue Date | 2011 |
| Publisher | 白血病183淋巴瘤 |
| Citation | 白血病·淋巴瘤.2011,20,(12),762-765. |
| Abstract | 滤泡性淋巴瘤(FL)是一种起源于B淋巴细胞的非霍奇金淋巴瘤( NHL),临床自然病程较长,表现惰性,初始治疗后易复发,传统的治疗方案多难以治愈.因此选择合适的治疗方案是延长患者生存时间的关键.利妥昔单抗、放射免疫治疗、苯达莫司汀等已被应用于FL的治疗.一些具有前景的新药如ofatumumab、依帕珠单抗(epratuzumab)、雷利度胺、硼替佐米、ABT-263等目前正在进行临床试验,这些新药将会为FL的治疗增加更多的选择. Follicular lymphoma (FL) is a type of B lymphocytic non-Hodgkin lymphoma.Clinically,FL presents with long course,indolent behavior,and is characterized by prompt response to initial therapy but almost invariably subsequent relapses.It is considered incurable with conventional therapies.Appropriate treatment strategies are critical for survival.Recently,several drugs such as rituximab,and bendamustine have been approved for FL treatment.Very promising novel agents like ofatumumab,epratuzumab,lenalidomide,bortezomib and ABT-263 are now under investigation in clinical trials and will provide more choices for FL therapy. |
| URI | http://hdl.handle.net/20.500.11897/110869 |
| ISSN | 1009-9921 |
| DOI | 10.3760/cma.j.issn.1009-9921.2011.12.020 |
| Appears in Collections: | 第三医院 |
